Cargando…

Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody

Dengue fever is caused by four different serotypes of dengue virus (DENV) which is the leading cause of worldwide arboviral diseases in humans. Virus-like particles (VLPs) containing flavivirus prM/E proteins have been demonstrated to be a potential vaccine candidate; however, the structure of dengu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Wen-Fan, Galula, Jedhan Ucat, Liu, Jyung-Hurng, Liao, Mei-Ying, Huang, Cheng-Hao, Wang, Yu-Chun, Wu, Han-Chung, Liang, Jian-Jong, Lin, Yi-Ling, Whitney, Matthew T, Chang, Gwong-Jen J, Chen, Sheng-Ren, Wu, Shang-Rung, Chao, Day-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234032/
https://www.ncbi.nlm.nih.gov/pubmed/30334522
http://dx.doi.org/10.7554/eLife.38970
Descripción
Sumario:Dengue fever is caused by four different serotypes of dengue virus (DENV) which is the leading cause of worldwide arboviral diseases in humans. Virus-like particles (VLPs) containing flavivirus prM/E proteins have been demonstrated to be a potential vaccine candidate; however, the structure of dengue VLP is poorly understood. Herein VLP derived from DENV serotype-2 were engineered becoming highly matured (mD2VLP) and showed variable size distribution with diameter of ~31 nm forming the major population under cryo-electron microscopy examination. Furthermore, mD2VLP particles of 31 nm diameter possess a T = 1 icosahedral symmetry with a groove located within the E-protein dimers near the 2-fold vertices that exposed highly overlapping, cryptic neutralizing epitopes. Mice vaccinated with mD2VLP generated higher cross-reactive (CR) neutralization antibodies (NtAbs) and were fully protected against all 4 serotypes of DENV. Our results highlight the potential of ‘epitope-resurfaced’ mature-form D2VLPs in inducing quaternary structure-recognizing broad CR NtAbs to guide future dengue vaccine design.